Yubo International Biotech Limited
YBGJ
Other OTC0.01
USD
- -
- -
CIK
0000895464
ISIN
US9883661004
CUSIP
988366100
Return %
Stock
S&P500
1Y
-89.35
18.21
3Y
-95.62
64.38
5Y
-96.68
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Yang Wang
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- Building 5 Beijing BE People's Republic of China
- IPO Date
- Aug 24, 2021
- CIK
- 0000895464
- Website
- yubogroup.com
- Similar Companies
- Business
- Yubo International Biotech Limited, formerly Magna-Lab Inc, operates as a holding company focused on the research, development and application of endometrial stem cells through its subsidiaries and primarily Yubo Beijing, offering products and services under the VIVCELL brand; core offerings include healthcare products for the respiratory system such as lung regulating essence nebulizers, skincare products like renewal essence mask powder and skin delicate essence, hair care products including tough curing hair follicles essence, healthy beverages such as cell basidiomycetes compound drinks, eye care products like eye moist essence, and male and female personal care products; the company also provides stem cell-related services encompassing cell testing and health management consulting. Yubo International Biotech Limited conducts operations in China, targets health-conscious consumers addressing issues like respiratory conditions, skin aging, hair loss and immunity, and maintains 18 employees. Incorporated in 1991 and headquartered at Room 105, Building 5, 31 Xishiku Avenue, Beijing, China, the company underwent a significant name change from Magna-Lab Inc to Yubo International Biotech Limited effective December 4, 2020, and completed a reverse merger with Platinum International Biotech Co., Ltd on January 14, 2021, alongside launching respiratory atomization products in April 2020 that generated approximately $1.7 million in accumulated sales.